Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus
Phase 4
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2013-03-28
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT00913367
- Locations
- 🇰🇷
HeeYoung Lee, Seoul, Korea, Republic of
Study Comparing Efficacy and Safety of Amaryl M and Metformin Uptitraion to Type 2 DM
Phase 4
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Glimepiride/metformin fixed combination
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2013-03-28
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 192
- Registration Number
- NCT00612144
- Locations
- 🇰🇷
Handok Pharmaceuticals, Co., LTD, Seoul, Korea, Republic of
Phase III Study for Glimepiride + Metformin Hydrochloride (Amaryl M) Slow Release (SR)
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 188
- Registration Number
- NCT00437554
- Locations
- 🇰🇷
Handok, Seoul, Korea, Republic of
Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study
Phase 4
Completed
- Conditions
- Prostatic Hyperplasia
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT00427882
- Locations
- 🇰🇷
Handok, Seoul, Korea, Republic of
Fexofenadine in Pruritic Skin Disease
Phase 4
Completed
- Conditions
- Pruritus
- First Posted Date
- 2005-12-02
- Last Posted Date
- 2007-11-07
- Lead Sponsor
- Handok Inc.
- Target Recruit Count
- 435
- Registration Number
- NCT00261079
- Locations
- 🇰🇷
Handok, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath